Jiangsu Hengrui Medicine Co Ltd Cash Flow-to-Debt Ratio
Jiangsu Hengrui Medicine Co Ltd cash flow-to-debt ratio. Jiangsu Hengrui Medicine Co Ltd (600276) has a Cash Flow-to-Debt Ratio of 0.58x as of September 2025, meaning its operating cash flow of CN¥4.81 Billion could theoretically repay 1% of its total liabilities (CN¥8.30 Billion) in one year. Check earnings quality score of Jiangsu Hengrui Medicine Co Ltd to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Jiangsu Hengrui Medicine Co Ltd (1999–2024)
Cash flow-to-debt ratio of Jiangsu Hengrui Medicine Co Ltd from 1999 to 2024. Historical debt coverage capacity for Jiangsu Hengrui Medicine Co Ltd across 26 annual periods. Check total reinvestment intensity of Jiangsu Hengrui Medicine Co Ltd to assess the company's total reinvestment commitment from operating cash flow.
Jiangsu Hengrui Medicine Co Ltd Cash Flow-to-Debt Ratio by Year (1999–2024)
Jiangsu Hengrui Medicine Co Ltd cash flow-to-debt ratio by year from 1999 to 2024. Year-by-year debt coverage analysis for Jiangsu Hengrui Medicine Co Ltd. For the full cash flow conversion analysis, see Jiangsu Hengrui Medicine Co Ltd (600276) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 1.83x | CN¥7.42 Billion | CN¥4.05 Billion | ▼ -34.0% |
| 2023 | 2.78x | CN¥7.64 Billion | CN¥2.75 Billion | ▲ +765.5% |
| 2022 | 0.32x | CN¥1.27 Billion | CN¥3.94 Billion | ▼ -71.9% |
| 2021 | 1.14x | CN¥4.22 Billion | CN¥3.69 Billion | ▲ +31.2% |
| 2020 | 0.87x | CN¥3.43 Billion | CN¥3.94 Billion | ▼ -40.3% |
| 2019 | 1.46x | CN¥3.82 Billion | CN¥2.62 Billion | ▲ +34.7% |
| 2018 | 1.08x | CN¥2.77 Billion | CN¥2.56 Billion | ▼ -10.9% |
| 2017 | 1.22x | CN¥2.55 Billion | CN¥2.10 Billion | ▼ -31.8% |
| 2016 | 1.78x | CN¥2.59 Billion | CN¥1.46 Billion | ▼ -10.9% |
| 2015 | 2.00x | CN¥2.28 Billion | CN¥1.14 Billion | ▲ +1.2% |
| 2014 | 1.98x | CN¥1.57 Billion | CN¥796.98 Million | ▼ -18.3% |
| 2013 | 2.42x | CN¥1.36 Billion | CN¥564.40 Million | ▲ +13.6% |
| 2012 | 2.13x | CN¥958.37 Million | CN¥450.01 Million | ▲ +77.5% |
| 2011 | 1.20x | CN¥527.36 Million | CN¥439.47 Million | ▲ +30.8% |
| 2010 | 0.92x | CN¥385.95 Million | CN¥420.80 Million | ▼ -30.3% |
| 2009 | 1.32x | CN¥439.12 Million | CN¥333.85 Million | ▲ +157.5% |
| 2008 | 0.51x | CN¥117.46 Million | CN¥229.91 Million | ▼ -11.2% |
| 2007 | 0.58x | CN¥218.87 Million | CN¥380.51 Million | ▼ -56.5% |
| 2006 | 1.32x | CN¥266.18 Million | CN¥201.07 Million | ▲ +2.9% |
| 2005 | 1.29x | CN¥227.88 Million | CN¥177.10 Million | ▲ +58.1% |
| 2004 | 0.81x | CN¥209.41 Million | CN¥257.33 Million | ▲ +225.6% |
| 2003 | 0.25x | CN¥136.82 Million | CN¥547.34 Million | ▲ +97.9% |
| 2002 | 0.13x | CN¥49.84 Million | CN¥394.60 Million | ▲ +296.9% |
| 2001 | 0.03x | CN¥11.49 Million | CN¥361.03 Million | ▼ -49.1% |
| 2000 | 0.06x | CN¥19.61 Million | CN¥313.71 Million | ▼ -44.5% |
| 1999 | 0.11x | CN¥33.89 Million | CN¥301.17 Million | — |